Research and development investments for biologics independently developed by US biotechnology startups, 2017–2023
Open Access
- 1 July 2025
- journal article
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 3 (7) , qxaf139
Abstract
Introduction: Despite policy interest in pharmaceutical innovation, little is known about the investment needed for venture capital–backed startups to develop innovative biologics, a growing segment of the pharmaceutical marketplace. Methods: In a cross-sectional analysis of Food and Drug Administration (FDA) drug approval data, investment deal records, and clinical trials data, we estimated the investment needed for a biotechnology startup company to independently develop a biologic approved by the US FDA with priority review, an indicator of innovation. To isolate a homogenous set of cases, the sample focused on independent drug development of 13 drugs by 9 biotechnology startup companies that retained ownership of the drug from the start of development to FDA approval without being acquired or licensing the product. Results: We found that the median investment per FDA-approved biologic was $304.1 million (IQR: $289.9–$790.3 million) in uncapitalized costs, accounting for the cost of failures. Conclusion: This estimate represents the direct drug R&D investment needed for independent development of innovative biologic products by biotechnology startup companies.Keywords
Funding Information
- Agency for Healthcare Research and Quality (T32HS000029)
This publication has 23 references indexed in Scilit:
- Differential Legal Protections for Biologics vs Small-Molecule Drugs in the USJAMA, 2024
- Costs of Drug Development and Research and Development Intensity in the US, 2000-2018JAMA Network Open, 2024
- The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene TherapiesPharmaceutical Medicine, 2023
- A Quantitative Framework to Identify and Prioritize Opportunities in Biomedical Product InnovationJAMA Health Forum, 2023
- Clinical development times for innovative drugsNature Reviews Drug Discovery, 2021
- Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018JAMA, 2020
- Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016JAMA Internal Medicine, 2018
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalJAMA Internal Medicine, 2017
- Investigating investment in biopharmaceutical R&DNature Reviews Drug Discovery, 2016
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016